Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
DOI:
https://doi.org/10.2340/actadv.v103.5578Keywords:
alopecia areata, upadacitinib, JAK inhibitors, pediatric, atopic dermatitisAbstract
Abstract is missing (Short communication)
Downloads
References
Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol 2020; 82: 675-682.
https://doi.org/10.1016/j.jaad.2019.08.032 DOI: https://doi.org/10.1016/j.jaad.2019.08.032
Andersen YM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol 2017; 76: 274-280.e1.
https://doi.org/10.1016/j.jaad.2016.08.047 DOI: https://doi.org/10.1016/j.jaad.2016.08.047
Barton VR, Toussi A, Awasthi S, Kiuru M. Treatment of pediatric alopecia areata: a systematic review. J Am Acad Dermatol 2022; 86: 1318-1334.
https://doi.org/10.1016/j.jaad.2021.04.077 DOI: https://doi.org/10.1016/j.jaad.2021.04.077
Lensing M, Jabbari A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Front Immunol 2022; 13: 955035.
https://doi.org/10.3389/fimmu.2022.955035 DOI: https://doi.org/10.3389/fimmu.2022.955035
King B, Ko J, Forman S, Ohyama M, Mesinkovska N, Yu G, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol 2021; 85: 847-853.
https://doi.org/10.1016/j.jaad.2021.05.050 DOI: https://doi.org/10.1016/j.jaad.2021.05.050
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687-1699.
https://doi.org/10.1056/NEJMoa2110343 DOI: https://doi.org/10.1056/NEJMoa2110343
Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol 2019; 80: 568-570.
https://doi.org/10.1016/j.jaad.2018.08.041 DOI: https://doi.org/10.1016/j.jaad.2018.08.041
Asfour L, Getsos Colla T, Moussa A, Sinclair RD. Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib. Int J Dermatol 2022; 61: e416-e417.
https://doi.org/10.1111/ijd.16316 DOI: https://doi.org/10.1111/ijd.16316
Cantelli M, Martora F, Patruno C, Nappa P, Fabbrocini G, Napolitano M. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther 2022; 35: e15346.
https://doi.org/10.1111/dth.15346 DOI: https://doi.org/10.1111/dth.15346
Gambardella A, Licata G, Calabrese G, De Rosa A, Alfano R, Argenziano G. Dual Efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata. Dermatitis 2021; 32: e85-e86.
https://doi.org/10.1097/DER.0000000000000780 DOI: https://doi.org/10.1097/DER.0000000000000780
Gori N, Cappilli S, Di Stefani A, Tassone F, Chiricozzi A, Peris K. Assessment of alopecia areata universalis successfully treated with upadacitinib. Int J Dermatol 2023; 62: e61-e63.
https://doi.org/10.1111/ijd.16342 DOI: https://doi.org/10.1111/ijd.16342
Le M, Berman-Rosa M, Ghazawi FM, Bourcier M, Fiorillo L, Gooderham M, et al. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Front Med (Lausanne) 2021; 8: 682547.
https://doi.org/10.3389/fmed.2021.682547 DOI: https://doi.org/10.3389/fmed.2021.682547
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Dianhe Yu, Yunqing Ren
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
